SCHEMBL3784667

SCHEMBL3784667

Cc1nc(N)nc(-n2c(Nc3ccc(NC(=O)c4ccc(C(C)(C)C)cc4)cc3)nc3ccccc32)n1

nearest known ligand 0.73

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MTOR P42345 19/20 0.73
PIK3CD O00329 18/20 0.73
PIK3CA P42336 18/20 0.73
PIK3CB P42338 18/20 0.73
PIK3CG P48736 18/20 0.73
INSR P06213 1/20 0.48
LCK P06239 1/20 0.48
LYN P07948 1/20 0.48
HCK P08631 1/20 0.48
SRC P12931 1/20 0.48
KDR P35968 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9948556 0.90 MTOR (0.74) MTORPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL3786290 0.87 MTOR (0.67) MTORPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL9949100 0.87 MTOR (0.78) MTORPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL3779707 0.86 MTOR (0.80) MTORPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL3791073 0.85 PIK3CD (0.67) MTORPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL3786614 0.85 MTOR (1.00) MTORPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL9948486 0.84 MTOR (0.71) MTORPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL9948679 0.84 MTOR (0.71) MTORPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL3787815 0.83 MTOR (1.00) MTORPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL9948493 0.83 MTOR (0.78) MTORPIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165334-A1 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors AMGEN INC. (US) 2012-06-28 US claimed
EP-2398791-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS Amgen, Inc (US) 2011-12-28 EP claimed
WO-2010096314-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS AMGEN INC. (US) 2010-08-26 WO claimed
US-20120165334-A1 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors AMGEN INC. (US) 2012-06-28 US disclosed
EP-2398791-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS Amgen, Inc (US) 2011-12-28 EP disclosed
WO-2010096314-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS AMGEN INC. (US) 2010-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165334-A1 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors MTOR, PIKFYVE, RICTOR MTOR 1/4885PIK3CD 8/4885PIK3CA 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.